Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Titan Pharmaceuticals stock opened at $4.34 on Tuesday. The firm has a market capitalization of $3.96 million, a price-to-earnings ratio of -0.94 and a beta of 1.25. The company’s 50 day simple moving average is $3.94 and its 200 day simple moving average is $3.75. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings data on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.